Figure 5

In vivo activity of BBR on murine xenograft B-lymphoma model. (a) Tumor size of xenograft B-cell lymphoma with subcutaneous injection of DB cells transfected with PCYT1A shRNA or control shRNA (CON shRNA, upper panel, N=5 for each group). Tumor size was measured in BBR group and the untreated group in xenograft B-cell lymphoma with subcutaneous injection of DB cells (lower panel, N=10 for each group). ***P<0.001, **P<0.01 and *P<0.05 comparing with the untreated group. (b) ¹¹C-Choline micro-positron emission tomography/computed tomography was performed one week after BBR treatment and standardized uptake value (SUV) intensity was observed. (c) PCYT1A and MYC expression were detected by immunohistochemistry. (d) Necroptosis and mitophagy were observed under transmission electron microscopy. (e) Serum levels of choline and its phosphorylated derivatives were measured by UPLC-triple quadrupole mass spectrometry. Data in a and e were represented as mean±s.e.m. Assay in e was set up in five mice.